FY2027 EPS Estimates for iTeos Therapeutics, Inc. Boosted by Wedbush (NASDAQ:ITOS)

iTeos Therapeutics, Inc. (NASDAQ:ITOS) – Wedbush upped their FY2027 earnings per share (EPS) estimates for shares of iTeos Therapeutics in a report issued on Sunday, September 15th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($6.51) per share for the year, up from their prior estimate of ($6.55). Wedbush currently has a “Outperform” rating and a $21.00 price objective on the stock. The consensus estimate for iTeos Therapeutics’ current full-year earnings is ($4.21) per share. Wedbush also issued estimates for iTeos Therapeutics’ FY2028 earnings at ($2.70) EPS.

iTeos Therapeutics (NASDAQ:ITOS) last announced its earnings results on Thursday, August 8th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($1.04) by $0.86. The company had revenue of $35.00 million during the quarter, compared to the consensus estimate of $4.20 million.

Other equities analysts have also issued research reports about the stock. HC Wainwright restated a “buy” rating and issued a $46.00 target price on shares of iTeos Therapeutics in a report on Monday. JPMorgan Chase & Co. lowered their price objective on iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating for the company in a research report on Monday, August 12th. Finally, Wells Fargo & Company began coverage on iTeos Therapeutics in a research report on Tuesday, August 13th. They set an “overweight” rating and a $31.00 target price on the stock.

iTeos Therapeutics Stock Performance

Shares of NASDAQ ITOS opened at $11.22 on Wednesday. The company’s 50 day moving average price is $16.12 and its 200-day moving average price is $14.63. iTeos Therapeutics has a 52-week low of $8.20 and a 52-week high of $18.75. The company has a market capitalization of $405.30 million, a P/E ratio of -2.97 and a beta of 1.39.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Candriam S.C.A. bought a new stake in iTeos Therapeutics in the second quarter valued at $7,558,000. Acadian Asset Management LLC acquired a new position in iTeos Therapeutics during the 1st quarter worth approximately $3,337,000. Clearline Capital LP acquired a new position in iTeos Therapeutics during the 2nd quarter worth approximately $2,328,000. Kennedy Capital Management LLC bought a new position in iTeos Therapeutics in the first quarter worth approximately $1,988,000. Finally, Dimensional Fund Advisors LP increased its holdings in shares of iTeos Therapeutics by 14.8% during the second quarter. Dimensional Fund Advisors LP now owns 908,329 shares of the company’s stock valued at $13,481,000 after acquiring an additional 117,159 shares in the last quarter. 97.16% of the stock is owned by institutional investors.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.